Johannesburg, Wednesday, 28 August 2024 — The BEAT Tuberculosis initiative has achieved a historic milestone in the fight against drug-resistant tuberculosis (DR-TB), becoming the world’s first project to address this issue across all population groups. The groundbreaking study has not only influenced local treatment guidelines but has also led to changes in international policies set by the World Health Organization (WHO).
Tuberculosis (TB) continues to be a major global health threat and is the second leading cause of death in South Africa. The BEAT Tuberculosis clinical study, which took place over the past six years at the Clinical HIV Research Unit (CHRU) Isango Lethemba TB Research Unit, involved research sites in the Eastern Cape and KwaZulu-Natal. This study emerged from South Africa’s urgent need to find more effective treatment options for DR-TB and has had a significant impact far beyond its initial scope.
The BEAT Tuberculosis initiative is a collaborative effort involving the National Department of Health, funding from the United States Agency for International Development (USAID), and execution by the University of the Witwatersrand. Its success has propelled the Global South to the forefront of TB treatment innovation.
Dr. Francesca Conradie, the principal investigator of the study, highlights its groundbreaking nature. “The BEAT Tuberculosis study represents a pioneering approach to TB research, especially with its inclusive methodology. By including pregnant women and children in the clinical trials, we’ve expanded our understanding of TB treatment’s safety and efficacy across diverse demographics. This success in proving the safety and effectiveness of a new short oral regimen in these key populations is a significant step towards a more inclusive and equitable approach to TB management,” she said.
The study aimed to compare the effectiveness and safety of a new, shortened treatment regimen for DR-TB with the current standard of care. Traditionally, the standard treatment required a seven-drug regimen over a minimum of nine months. In contrast, the new regimen involved four to five medications, including newer drugs like Bedaquiline and Delamanid, administered over just six months.
An additional objective of the BEAT Tuberculosis study was to build research capacity for DR-TB in the Eastern Cape and KwaZulu-Natal. This included enhancing community engagement and training healthcare personnel in clinical research methodologies. The support from the National and Provincial Departments of Health was crucial, providing necessary medication and laboratory infrastructure for assessing treatment safety and efficacy.
Despite the challenges posed by the COVID-19 pandemic, the study enrolled over 400 participants across various sites in the Eastern Cape and KwaZulu-Natal since its inception in 2019.
Prof. Norbert Ndjeka, Chief Director for TB Control and Management at the National Department of Health, emphasises the study’s importance. “In South Africa, approximately 280,000 people developed TB in 2022, with 54,000 deaths from the disease. The BEAT Tuberculosis project is a remarkable effort to advance TB treatment and research. Originally intended to inform local guidelines, the results now have the potential to transform TB management globally,” he said.
USAID, a key funding partner in this initiative, plays a significant role in global TB care improvements. Leslie Marbury, USAID Southern Africa Mission Director, celebrated the milestone:
“In partnership with South Africa’s National Department of Health, USAID has supported significant advancements in TB patient care worldwide. We honour the 400 participants whose contributions made this trial possible and thank all the BEAT Tuberculosis stakeholders for their dedication.”
For those experiencing symptoms of TB, such as a persistent cough lasting more than two weeks, weight loss, night sweats, and fever, it is crucial to seek medical attention at a local clinic. A sputum test will be conducted to confirm the presence of TB, and appropriate treatment will be initiated if the test is positive.
The BEAT Tuberculosis initiative stands as a beacon of hope in the global fight against TB, showing how local research and collaboration can lead to significant advances in global health.
ALSO READ: Breakthrough in the development of tumor-targeting treatment
